HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Files An 8-K Regulation FD Disclosure

On December 28, 2017, Helius Medical Technologies, Inc. (the “Company”) issued a press release announcing the closing of the $1.7 million second tranche of a private placement of shares of Class A Common Stock and warrants (the “Private Placement”). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

On December 29, 2017, the Company issued a press release announcing the closing of the $2.0 million third and final tranche of the Private Placement.The aggregate gross proceeds of the Private Placement were $6.3 million.A copy of the press release is attached as Exhibit 99.2 to this Report.

The information in this Report, including Exhibits 99.1 and 99.2 hereto, is furnished to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

This Report, and Exhibits 99.1 and 99.2 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1, Exhibit 99.2 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

HELIUS MEDICAL TECHNOLOGIES, INC. ExhibitEX-99.1 2 hsdt-ex991_6.htm EX-99.1 hsdt-ex991_6.htm Exhibit 99.1 Helius Medical Technologies Announces Closing of Second Tranche of Private Placement   NEWTOWN,…To view the full exhibit click here
About HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT)
Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.